Definitive Proxy Filed for Redx Reverse Merger — Skye Holders Left with Just 5.38%

summarizeSummary

Definitive proxy materials for the reverse merger with Redx Pharma have been filed. Skye shareholders will own just 5.38% of the combined company, with Redx holders at 46.17% and new investors at 48.45%. The deal includes $103.9M in financing and a 1-for-8 reverse stock split.

check_boxKey Events · M&A and Partnerships · SKYE

• Reverse Merger with Redx Pharma

  Skye will acquire Redx Pharma via a UK scheme of arrangement. Ownership of the combined company will be split with Skye shareholders at only 5.38%, Redx holders at 46.17%, and new investors at 48.45%.

• Valuation Disparity

  The valuation gap is significant: Skye is valued at $14.5M (subject to a $2M floor) while Redx is valued at $125M, underscoring Redx's dominance in the combined entity.

• Financing Package

  The financing package includes a $67.9M concurrent financing (up to $72.9M), a $36M Series A financing, a $22M equity line of credit, and a $5M warrant to Redmile Group.

• 1-for-8 Reverse Stock Split

  A 1-for-8 reverse stock split takes effect August 24, 2026, reducing authorized shares from 300M to 37.5M and outstanding shares from 35.4M to approximately 4.4M.

auto_awesomeAnalysis · SKYE · Life Sciences

The definitive proxy materials for the reverse merger with Redx Pharma have been filed, and the ownership math is stark: Skye shareholders will retain only 5.38% of the combined company, while Redx holders claim 46.17% and new investors take 48.45%. The full Transaction Agreement reveals a $14.5M valuation for Skye against $125M for Redx, alongside a $67.9M concurrent financing, a $36M Series A financing, a $22M equity line, and a 1-for-8 reverse stock split effective August 24, 2026. This is a transformative event that fundamentally reshapes Skye's ownership and future.